on August 12, 2021, the FDA expanded its approval to include the treatment of idiopathic hypersomnia (IH) in adults.

Jul 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved Inqovi on July 7, 2020, for the treatment of certain types of myelodysplastic syndromes (MDS).

Pierre Fabre Laboratories have received European marketing approval for OBGEMSA™ (vibegron) to treat overactive bladder.

Jul 3rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

KBio Receives FDA IND Approval for EV68-228-N to Treat Acute Flaccid Myelitis and Begins Phase 1 Trial with First Patient Dosed.

The U.S. Food and Drug Administration (FDA) approved Rukobia on July 2, 2020, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

GT Biopharma Gets FDA Approval for IND Application for GTB-3650, an NK Cell Engager Targeting CD33+ Leukemia.

The U.S. Food and Drug Administration (FDA) approved Dojolvi on June 30, 2020, for the treatment of long-chain fatty acid oxidation disorders (LC-FAODs) in adults and children.

Elicio Therapeutics Presents Initial Disease-Free Survival Data from the Phase 1a AMPLIFY-7P Study of ELI-002 7P.

The U.S. Food and Drug Administration (FDA) approved Phesgo on June 29, 2020, for the treatment of HER2-positive breast cancer.

Ensho Therapeutics revealed that it has secured a portfolio of oral α4β7 integrin inhibitors under an exclusive global license agreement with EA Pharma Co., Ltd., a division of Eisai Co., Ltd.